LLY

740.2

+0.33%↑

JNJ

154.19

-0.51%↓

ABBV

185.54

+0.02%↑

NVO

72.27

+1.32%↑

UNH

308.12

+2.39%↑

LLY

740.2

+0.33%↑

JNJ

154.19

-0.51%↓

ABBV

185.54

+0.02%↑

NVO

72.27

+1.32%↑

UNH

308.12

+2.39%↑

LLY

740.2

+0.33%↑

JNJ

154.19

-0.51%↓

ABBV

185.54

+0.02%↑

NVO

72.27

+1.32%↑

UNH

308.12

+2.39%↑

LLY

740.2

+0.33%↑

JNJ

154.19

-0.51%↓

ABBV

185.54

+0.02%↑

NVO

72.27

+1.32%↑

UNH

308.12

+2.39%↑

LLY

740.2

+0.33%↑

JNJ

154.19

-0.51%↓

ABBV

185.54

+0.02%↑

NVO

72.27

+1.32%↑

UNH

308.12

+2.39%↑

Search

Beam Therapeutics Inc

Open

SectorHealthcare

16.2 2.27

Overview

Share price change

24h

Current

Min

15.65

Max

16.61

Key metrics

By Trading Economics

Income

-19M

-109M

Sales

-23M

7.5M

EPS

-1.242

Profit margin

-1,462.784

Employees

393

EBITDA

-29M

-114M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+185.15% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-301M

1.7B

Previous open

13.93

Previous close

16.2

News Sentiment

By Acuity

72%

28%

337 / 381 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Beam Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Sept 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer Comparison

Price change

Beam Therapeutics Inc Forecast

Price Target

By TipRanks

185.15% upside

12 Months Forecast

Average 45.14 USD  185.15%

High 80 USD

Low 20 USD

Based on 15 Wall Street analysts offering 12 month price targets forBeam Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

13

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

16.225 / 20.17Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

337 / 381 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.